CLINICAL TRIALS PROFILE FOR CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

All Clinical Trials for CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00187655 ↗	Effect of, OAT3, on the Renal Secretion of Cefotaxime	Completed	University of California, San Francisco	Phase 1	2004-01-01	In the proposed study, we plan to use a genotype to phenotype strategy to study the role of the organic anion transporter, OAT3, in drug response. More specifically we will examine the contribution of OAT3 to the renal clearance of anionic drugs such as cefotaxime by studying individuals with a non-functional (or poorly-functional) variant of OAT3.
NCT02560207 ↗	Randomized Trial of Continuous Versus Intermittent Cefotaxime Infusion on ICU.	Completed	University Medical Center Groningen	Phase 4	2015-11-01	This study evaluates target attainment after either intermittent intravenous bolus or intravenous continuous infusion of cefotaxime in critically ill patients. Critically ill patients will be randomized to intermittent infusion or continuous infusion of cefotaxime.
NCT02959957 ↗	Disturbance of the Intestinal Microbiota by Temocillin vs Cefotaxime in Treatment of Febrile Urinary Tract Infections	Completed	Håkan Hanberger	Phase 4	2016-05-20	This study will evaluate the ecological impact on the intestinal microbiota and compare the safety and efficacy of temocillin compared to cefotaxime, in empiric treatment of febrile UTI. Half of participants will receive temocillin and the other half will receive cefotaxime.

Clinical Trial Conditions for CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

Condition Name

Condition Name for CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER
Intervention	Trials
Critically Ill	1
Focus Groups	1
Urinary Tract Infections	1

Condition MeSH

Condition MeSH for CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER
Intervention	Trials
Urinary Tract Infections	1
Infections	1
Infection	1

Clinical Trial Locations for CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

Trials by Country

Trials by Country for CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER
Location	Trials
Sweden	2
Netherlands	1

Clinical Trial Progress for CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Phase 4	2
Phase 1	1

Clinical Trial Status

Clinical Trial Status for CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Completed	3

Clinical Trial Sponsors for CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER
Sponsor	Trials
University of California, San Francisco	1
University Medical Center Groningen	1
Håkan Hanberger	1

Sponsor Type

Sponsor Type for CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER
Sponsor	Trials
Other	3

Last updated: May 23, 2026

Claforan in Dextrose 5% in Plastic Container (Cefotaxime) Clinical Trials Update, Market Analysis and Sales Projection

No complete, accurate clinical-trials and market-projection dataset can be produced from the information provided.

What clinical trials involve Claforan in dextrose 5% plastic container (cefotaxime)?

Not enough information is available to compile a verified list of active, completed, or planned trials, or to map them to the specific dosage form “in dextrose 5% in plastic container.”

Which indications are being studied for cefotaxime IV?

Insufficient data to identify indication-specific trials tied to this exact presentation.

What are the latest trial outcomes (phase, endpoints, recruitment status)?

No verified, presentation-specific trial results can be generated.

How big is the market for cefotaxime injection, and who sells it?

A quantified market size and share outlook cannot be calculated from the provided input.

What is the current competitive landscape for cefotaxime IV products?

No verified manufacturer-specific breakdown can be produced for “Claforan in dextrose 5% in plastic container.”

How is demand changing by region (US/EU/LatAm/Asia)?

No regional demand dataset is available in the provided material.

When does the Claforan in dextrose 5% plastic container product face generic competition risk?

A forecast of launch risk requires Orange Book listings, patent estate mapping, exclusivity status, and regulatory-history details that are not provided.

What FDA status applies to this specific presentation?

No FDA labeling or approval/changes history is available to support regulatory status reporting.

What settlement or exclusivity events affect cefotaxime injection?

No litigation or settlement record is available in the provided material.

How do clinical-trial signals affect pricing and unit demand for cefotaxime IV?

No causally grounded projection can be produced without trial-to-market linkage data (label expansion, new endpoints leading to guideline changes, or contracted formulary behavior).

What sales projection model is appropriate for Claforan in dextrose 5% plastic container?

A defensible sales projection requires baseline units/revenue, payer mix, hospital utilization trends, and product-level share. None is included.

Key Takeaways

• A clinical-trials update and a quantified market analysis for the specific product presentation “Claforan in dextrose 5% in plastic container” cannot be produced from the provided information.
• No accurate projections can be generated without verified FDA/regulatory, competitive, and sales baseline data.

FAQs

1. What clinical trial phases are most common for cefotaxime injection updates?
2. How does cefotaxime IV utilization differ between hospital and outpatient settings?
3. What drives procurement shifts among third-generation cephalosporins versus piperacillin-tazobactam?
4. How do FDA labeling changes typically impact hospital formulary adoption for cefotaxime products?
5. What metrics are used to project demand for IV antibiotics in hospital systems?